Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

2 cheap stocks I think Warren Buffett would love

As a long-term investor, I could do a lot worse than listen to a stock-investing genius like Warren Buffett. Here are two top stocks I think he’d approve of.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Warren Buffett is one of the most successful, and by extension most famous, value-loving investors in the business. Picking low-cost stocks with his Berkshire Hathaway firm and watching them balloon in value has made the ‘Sage of Omaha’ worth an estimated $100.4bn today.

But Buffett’s investing strategy is about much more than just identifying undervalued stocks. Here are two cheap UK shares I think would whet the billionaire investor’s appetite for other reasons.

The FTSE 100 pharma giant

Buying companies which have clear and effective ‘economic moats’ is a cornerstone of Buffett’s money-making strategy. This is the name given to any long-term advantage a business has over the competition. They can include anything from market-leading products and a lower cost base versus rival operators, to creating high switching costs for customers looking to take their custom elsewhere.

GlaxoSmithKline (LSE: GSK) has one of the most formidable economic moats out there, namely significant patent protection. This stops rival drugs manufacturers moving in and copying its expensively-assembled portfolio of world-class treatments. According to DrugPatentWatch, the FTSE 100 company has 1,048 product patents in effect spanning 59 countries.

Pharmaceuticals development is a notoriously difficult business. And GlaxoSmithKline’s great track record of producing market-leading patented products is no guarantee of future success. But I’d argue that this UK share’s undemanding forward price-to-earnings (P/E) ratio of around 13 times still offers terrific value. Especially considering its strong position in many fast-growing therapy areas like oncology, vaccines and respiratory disorders, and the enormous financial clout it has to plough into R&D.

I think Buffett, who already owns Merck and Bristol Myers Squibb, would love this UK share.

Another stock Warren Buffett might adore

The popularity of Britvic’s (LSE: BVIC) brands seems to be timeless. The likes of Pepsi, Robinsons, Lipton and R Whites have been keeping consumers refreshed for many decades (some even have their roots in the 1800s). And their popularity is a strong as ever.

Buffett loves firms with robust brand power, as shown by Berkshire Hathaway’s holdings in Apple, Kraft Heinz and Coca-Cola. This economic moat helps demand for their products grow stronger than the broader market when consumer spending comes under pressure. It also allows companies like Britvic to raise prices without having to worry too much about how this will affect sales volumes.

I think Britvic’s a top buy despite the threat posed by a growing carbon dioxide shortage, a critical component in the company’s fizzy drinks. European fertilizer plants are shutting down operations in response to soaring energy prices, including two major facilities here in the UK. This could naturally damage beverages production and jack up costs considerably.

City analysts currently think Britvic’s earnings will jump 24% in the upcoming financial year (to September 2022). This leaves it trading on a bargain-basement forward price-to-earnings growth (PEG) ratio of 0.7. In my opinion, this provides the sort of bang for your buck that value investors like Warren Buffett adore.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended Apple and Bristol Myers Squibb. The Motley Fool UK has recommended Britvic and GlaxoSmithKline and has recommended the following options: long March 2023 $120 calls on Apple and short March 2023 $130 calls on Apple. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

Forget high yields? Here’s the smart way to build passive income with dividend shares

Stephen Wright outlines how investors looking for passive income can put themselves in the fast lane with dividend shares.

Read more »

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

15,446 Diageo shares gets me a £1,000 monthly second income. Should I?

Diageo has been a second-rate income stock for investors over the last few years. But the new CEO sees potential…

Read more »

Investing Articles

2 FTSE 100 stocks to target epic share price gains in 2026!

Looking for blue-chip shares to buy? Discover which two FTSE 100 stocks our writer Royston Wild thinks could explode in…

Read more »

A row of satellite radars at night
Investing Articles

If the stock market crashes in 2026, I’ll buy these 2 shares like there’s no tomorrow

These two shares have already fallen 25%+ in recent weeks. So why is this writer wating for a stock market…

Read more »

British Pennies on a Pound Note
Investing Articles

How much money does someone really need to start buying shares?

Could it really be possible to start buying shares with hundreds of pounds -- or even less? Christopher Ruane weighs…

Read more »

Two gay men are walking through a Victorian shopping arcade
Investing Articles

With Versace selling for £1bn, what does this tell us about the valuations of the FTSE 100’s ‘fashionable’ stocks?

Reflecting on the sale of Versace, James Beard reckons the valuations of the FTSE 100’s fashion stocks don’t reflect the…

Read more »

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

Want to stuff your retirement portfolio with high-yield shares? 5 to consider that yield 5.6%+

Not everyone wants to have a lot of high-yield shares in their portfolio. For those who might, here's a handful…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How much do you need in a SIPP to target a £3,658 monthly passive income?

Royston Wild discusses a 9.6%-yielding fund that holds global stocks -- one he thinks could help unlock an enormous income…

Read more »